Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLR5 | ISIN: US00650F1093 | Ticker-Symbol: 1HM
Frankfurt
25.04.25
08:06 Uhr
6,862 Euro
+0,230
+3,47 %
1-Jahres-Chart
ADAPTIVE BIOTECHNOLOGIES CORPORATION Chart 1 Jahr
5-Tage-Chart
ADAPTIVE BIOTECHNOLOGIES CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
6,8387,04412:31
6,8387,04412:31

Aktuelle News zur ADAPTIVE BIOTECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ADAPTIVE BIOTECHNOLOGIES Aktie jetzt für 0€ handeln
02:30Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock2
10.04.Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 20252
08.04.Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Surveillance in Mantle Cell Lymphoma1
21.03.Analyst Expectations For Adaptive Biotechnologies' Future2
21.03.Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday10
03.03.Adaptive Biotechnologies Corp - 10-K, Annual Report-
22.02.Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies110
21.02.Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock10
12.02.Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements10
11.02.Adaptive Biotechnologies Q4 Loss Declines3
11.02.Adaptive Biotechnologies GAAP EPS of -$0.23 beats by $0.02, revenue of $47.46M beats by $1.41M9
11.02.Adaptive Biotechnologies Corp - 8-K, Current Report-
10.02.Adaptive Biotechnologies Q4 2024 Earnings Preview1
23.01.Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now5
23.01.Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now?5
14.01.Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients11
07.01.Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ Test for Minimal Residual Disease Assessment is Effective as of January 1st, 20252
08.12.24Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions156New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment...
► Artikel lesen
03.12.24Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting6
07.11.24Adaptive Biotechnologies Q3 Loss Decreases, Beats Estimates23
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1